Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
 
(29 intermediate revisions by 3 users not shown)
Line 6: Line 6:
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
  
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
 
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
 
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
 
  
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
+
*[[Media:Supplement_QIBA_AmyloidPET_3Jun2022_TechnicallyConfirmed.pdf | PET Amyloid 2022-06-03]]  
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
  
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
+
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]
  
 +
* [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
  
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
+
* [[Media:QIBA CTVol TumorVolumeChangeProfile TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
 +
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
 +
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
  
*[[Media:QIBA_CT_Lung_Density_Profile_090420-clean.pdf | QIBA CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
+
* [[Media:QIBA FDG-PET Profile v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]  
+
:*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
  
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
+
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
*[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
+
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 +
:*[[Media:QIBA CTA Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]]
  
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]  
+
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]
  
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]  
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification v1.0 2012-08-08]]
  
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
+
*[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
  
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
+
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
  
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
+
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf| MR Elastography of the Liver 2018-05-02]]
  
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
+
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK cartilage for joint disease 2021-09-25]]
  
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
+
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
  
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
+
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
 +
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
  
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
+
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
+
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis-2022-04-25]] ('''closed''' on May 3, 2022)
 +
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022)
  
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - Thursday, October 29, 2020 [extended]'''</font>)
+
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles ===
  
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
+
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
  
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021)
  
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | CT Lung Density 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
+
*[[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020)
  
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] ('''closed''' on October 16, 2019)
+
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
  
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
 
  
 
+
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
 
  
  
Line 64: Line 65:
 
Cite QIBA Profile documents as:
 
Cite QIBA Profile documents as:
  
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
+
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
  
 
Example:
 
Example:
  
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
+
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
 +
 
  
 
====Statements of Endorsement====
 
====Statements of Endorsement====
Line 75: Line 77:
 
*[[Additional letters of support can be found here]]
 
*[[Additional letters of support can be found here]]
  
====See Also====
+
 
 +
==== See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Latest revision as of 00:08, 14 June 2022

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

  • Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
  • Assessment Procedures (refer to Section 4 in the Profile document - pg 30)

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also